scholarly journals A Pilot Study of 18F-FLT PET/CT in Pediatric Lymphoma

2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Danny L. Costantini ◽  
Reza Vali ◽  
Susan McQuattie ◽  
Jeffrey Chan ◽  
Angela Punnett ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Pilot Study ◽  
Clinical Utility ◽  
Adverse Reactions ◽  
Future Studies ◽  
Pediatric Lymphoma ◽  
Flt Pet ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

We performed an observational pilot study of 18F-FLT PET/CT in pediatric lymphoma. Eight patients with equivocal 18F-FDG PET/CT underwent imaging with 18F-FLT PET/CT. No immediate adverse reactions to 18F-FLT were observed. Compared to 18F-FDG, 18F-FLT uptake was significantly higher in bone marrow and liver (18F-FLT SUV 8.6±0.6 and 5.0±0.3, versus 18F-FDG SUV 1.9±0.1 and 3.4±0.7, resp., p<0.05). In total, 15 lesions were evaluated with average 18F-FDG and 18F-FLT SUVs of 2.6±0.1 and 2.0±0.4, respectively. Nonspecific uptake in reactive lymph nodes and thymus was observed. Future studies to assess the clinical utility of 18F-FLT PET/CT in pediatric lymphoma are planned.

scholarly journals Head and neck tumors angiogenesis imaging with 68Ga-NODAGA-RGD in comparison to 18F-FDG PET/CT: a pilot study

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Steve Durante ◽  
Vincent Dunet ◽  
François Gorostidi ◽  
Periklis Mitsakis ◽  
Niklaus Schaefer ◽  
...  
Keyword(s):  
Pilot Study ◽  
Head And Neck ◽  
Fdg Pet ◽  
Head And Neck Tumors ◽  
Neck Tumors ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

68Ga-FAPI-04 PET/CT, a new step in breast cancer imaging: a comparative pilot study with the 18F-FDG PET/CT

2021 ◽  
Author(s):  
Halil Kömek ◽  
Canan Can ◽  
Yunus Güzel ◽  
Zeynep Oruç ◽  
Cihan Gündoğan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Pilot Study ◽  
Fdg Pet ◽  
Cancer Imaging ◽  
Breast Cancer Imaging ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Aggressive systemic mastocytosis with diffuse bone marrow 18F-FDG uptake

2021 ◽  
Author(s):  
Renata Koukalová ◽  
Jiří Vašina ◽  
Jiří Štika ◽  
Michael Doubek ◽  
Petr Szturz
Keyword(s):  
Bone Marrow ◽  
Digestive System ◽  
Systemic Mastocytosis ◽  
Primary Tumour ◽  
Bone Marrow Involvement ◽  
Abdominal Ct ◽  
Splenic Parenchyma ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

AbstractMastocytosis is a clonal hematopoietic disorder characterized by proliferation of abnormal mast cells in various organs including the skin, digestive system, lymph nodes, and bone marrow. We report on a 75-year-old woman presenting with abdominal pain, vomiting, diarrhoea, myalgia, and weight loss. Abdominal CT showed hepatosplenomegaly with heterogeneous splenic parenchyma, lymphadenopathy, and osteopenia with areas of osteosclerosis but no primary tumour. An 18F-FDG PET/CT revealed an overall low metabolic activity of the lesions with a diffuse bone marrow involvement raising suspicion of a haematological neoplasm. Subsequently, bone marrow and peripheral blood examinations confirmed the diagnosis of aggressive systemic mastocytosis.

scholarly journals Can 18F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma?

Cancers ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 1335
Author(s):  
Christos Sachpekidis ◽  
Annette Kopp-Schneider ◽  
Maximilian Merz ◽  
Anna Jauch ◽  
Marc-Steffen Raab ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Infiltration Rate ◽  
Reference Tissue ◽  
Pet Ct ◽  
Bone Marrow Plasma ◽  
18F Fdg ◽  
Fdg Pet Ct

There is an unmet need for positron emission tomography (PET) radiotracers that can image bone disease in multiple myeloma (MM) in a more sensitive and specific way than the widely used 18F-fluorodeoxyglucose (18F-FDG). Sodium fluoride (18F-NaF) is a highly sensitive tracer of bone reconstruction, evolving as an important imaging agent for the assessment of malignant bone diseases. We attempted to investigate for the first time the prognostic significance of 18F-NaF PET/CT in newly diagnosed, symptomatic MM patients planned for autologous stem cell transplantation (ASCT). Forty-seven patients underwent dynamic and static PET/CT with 18F-NaF before treatment. After correlation with the respective findings on CT and 18F-FDG PET/CT that served as reference, the 18F-NaF PET findings were compared with established factors of high-risk disease, like cytogenetic abnormalities as well as bone marrow plasma cell infiltration rate. Furthermore, the impact of 18F-NaF PET/CT on progression-free survival (PFS) was analyzed. Correlation analysis revealed a moderate, significant correlation of the 18F-NaF parameters SUVaverage and K1 in reference tissue with bone marrow plasma cell infiltration rate. However, no significant correlation was observed regarding all other 18F-NaF PET parameters. Survival analysis revealed that patients with a pathologic 18F-NaF PET/CT have a shorter PFS (median = 36.2 months) than those with a physiologic scan (median = 55.6 months) (p = 0.02). Nevertheless, no quantitative 18F-NaF parameter could be shown to adversely affect PFS. In contrast, the respective analysis for quantitative dynamic 18F-FDG PET/CT revealed that the parameters SUVmax, fractional blood volume (VB), k3 and influx from reference tissue as well as SUVaverage from MM lesions had a significant negative impact on patient survival. The herein presented findings highlight the rather limited role of 18F-NaF PET/CT as a single PET approach in MM.

Bone marrow MRI versus 18F-FDG-PET/CT for detecting multiple myeloma lesions: diagnostic performance and clinical relevance

2019 ◽  
Vol 19 (10) ◽  
pp. e35-e36
Author(s):  
Frédéric Lecouvet ◽  
Dimitar Boyadzhiev ◽  
Laurence Collette ◽  
Maude Berckmans ◽  
Nicolas Michoux ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Fdg Pet ◽  
Clinical Relevance ◽  
Diagnostic Performance ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals 18F-FLT-PET/CT adds value to 18F-FDG-PET/CT for diagnosing relapse after definitive radiotherapy in patients with lung cancer. Results of a prospective clinical trial

2020 ◽  
pp. jnumed.120.247742
Author(s):  
Tine Noehr Christensen ◽  
Seppo W Langer ◽  
Gitte F Persson ◽  
Klaus Richter Larsen ◽  
Annika Loft ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Trial ◽  
Fdg Pet ◽  
Prospective Clinical Trial ◽  
Definitive Radiotherapy ◽  
Flt Pet ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Clinical Utility of [18F]FDG-PET /CT in Pericardial Disease

2019 ◽  
Vol 21 (9) ◽  
Author(s):  
Min-Sun Kim ◽  
Eun-Kyung Kim ◽  
Joon Young Choi ◽  
Jae K. Oh ◽  
Sung-A Chang
Keyword(s):  
Fdg Pet ◽  
Clinical Utility ◽  
Pericardial Disease ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals [18F]FDG-PET/CT Radiomics for Prediction of Bone Marrow Involvement in Mantle Cell Lymphoma: A Retrospective Study in 97 Patients

Cancers ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 1138 ◽  
Author(s):  
Marius E. Mayerhoefer ◽  
Christopher C. Riedl ◽  
Anita Kumar ◽  
Ahmet Dogan ◽  
Peter Gibbs ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Fdg Pet ◽  
Cell Lymphoma ◽  
Bone Marrow Involvement ◽  
Laboratory Data ◽  
Texture Features ◽  
Pet Ct ◽  
Mantle Cell ◽  
18F Fdg ◽  
Fdg Pet Ct

Biopsy is the standard for assessment of bone marrow involvement in mantle cell lymphoma (MCL). We investigated whether [18F]FDG-PET radiomic texture features can improve prediction of bone marrow involvement in MCL, compared to standardized uptake values (SUV), and whether combination with laboratory data improves results. Ninety-seven MCL patients were retrospectively included. SUVmax, SUVmean, SUVpeak and 16 co-occurrence matrix texture features were extracted from pelvic bones on [18F]FDG-PET/CT. A multi-layer perceptron neural network was used to compare three combinations for prediction of bone marrow involvement—the SUVs, a radiomic signature based on SUVs and texture features, and the radiomic signature combined with laboratory parameters. This step was repeated using two cut-off values for relative bone marrow involvement: REL > 5% (>5% of red/cellular bone marrow); and REL > 10%. Biopsy demonstrated bone marrow involvement in 67/97 patients (69.1%). SUVs, the radiomic signature, and the radiomic signature with laboratory data showed AUCs of up to 0.66, 0.73, and 0.81 for involved vs. uninvolved bone marrow; 0.68, 0.84, and 0.84 for REL ≤ 5% vs. REL > 5%; and 0.69, 0.85, and 0.87 for REL ≤ 10% vs. REL > 10%. In conclusion, [18F]FDG-PET texture features improve SUV-based prediction of bone marrow involvement in MCL. The results may be further improved by combination with laboratory parameters.

scholarly journals Bone Marrow and Tumor Radiomics at 18F-FDG PET/CT: Impact on Outcome Prediction in Non–Small Cell Lung Cancer

Radiology ◽  
2019 ◽  
Vol 293 (2) ◽  
pp. 451-459 ◽  
Author(s):  
Sarah A. Mattonen ◽  
Guido A. Davidzon ◽  
Jalen Benson ◽  
Ann N. C. Leung ◽  
Minal Vasanawala ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Bone Marrow ◽  
Small Cell Lung Cancer ◽  
Fdg Pet ◽  
Outcome Prediction ◽  
Small Cell ◽  
Small Cell Lung ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct
Sign in / Sign up

Export Citation Format

Share Document